HCMHUTCHMED (China) Limited
Is the business good?
How good a business is HCM?
HUTCHMED (China) Limited keeps −71% of every revenue dollar as operating profit, against 9.5% for the median Drug Manufacturers - Specialty & Generic name.
Operating margin · Drug Manufacturers - Specialty & Generic median 9.5% · 12 months to Q4 2019
- R&D as % of revenue
- 67%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −86% |
| FY2021 | −92% |
| FY2022 | −96% |
| FY2023 | 2.2% |
| FY2024 | −6.9% |
| FY2025 | −7.1% |
Details›
- Operating margin12 months to Q4 2019
- −71%
- Net margin12 months to Q4 2019
- −52%
- Free cash flow margin
- −44%
- R&D as % of revenue
- 67%
- Revenue, trailing twelve months
- $205M
- Free cash flow, trailing twelve months
- −$89M
- Net income, trailing twelve months
- −$106M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Customers and suppliers
Who buys from HCM and who it buys from, as the companies report it.
- Largest customer26%
Share of revenue · FY2025 20-F
- Five largest customers62%
Combined share of revenue · FY2025 20-F
None disclosed.
A company has to disclose every customer behind 10% or more of its revenue. Each share comes from the latest annual report of the company that states it and shows on both companies’ pages; HCM’s own figures are from its FY2025 20-F. Smaller customers and suppliers go unreported.
Drug Manufacturers, Specialty & Generic
Ranks #37 of 39 by RyuScore